Skip to main content

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia



The interest of health care agencies, private payers and policy makers for patient-reported outcomes (PRO) is continuously increasing. There is a substantial need to improve capacity to collect and interpret relevant PRO data to support implementation of patient-centered research and optimal care in haemophilia. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project aims to develop a patient-led research network, to develop a standardized questionnaire to gather patient-reported outcomes and to perform a feasibility study of implementing the PROBE questionnaire.


A pilot questionnaire was developed using focus group methodology. Content and face validity were assessed by a pool of persons living with haemophilia (PWH) and content experts through interactive workshops. The PROBE questionnaire was translated with the forward-backward approach. PROBE recruited national haemophilia patient non-governmental organizations (NGOs) to administer the questionnaire to people with and without haemophilia. PROBE measured the time to complete the questionnaire and gathered feedback on its content and clarity; staff time and cost required to implement the questionnaire were also collected.


The PROBE questionnaire is comprised of four major sections (demographic data, general health problems, haemophilia-related health problems and health-related quality of life using EQ-5D-5L and EQ-VAS). Seventeen NGOs participated in the pilot study of the PROBE Project, recruiting 656 participants. Of these, 71% completed the questionnaire within 15 min, and all participants completed within 30 min. The median total staff and volunteer time required for the NGOs to carry out the study within their country was 9 h (range 2 to 40 h). NGO costs ranged from $22.00 to $543.00 USD per country, with printing and postage being the most commonly reported expenditures.


The PROBE questionnaire assesses patient-important reported outcomes in PWH and control participants, with a demonstrated short completion time. PROBE proved the feasibility to engage diverse patient communities in the structured generation of real-world outcome research at all stages.

Trial registration

Trial registration: NCT02439710.

Peer Review reports


Haemophilia is an inherited bleeding disorder, caused by a deficiency of coagulation factor VIII (haemophilia A) or factor IX (haemophilia B). Persons living with haemophilia (PWH) experience various degrees of bleeding, depending on residual coagulation factor levels [1]. Bleeding occurs most commonly in joints, soft tissue and muscles [2], causing short-term symptoms (acute bleeding, acute pain) [3] and long-term complications (chronic pain, haemophilic arthropathy, or disability) [4, 5]. Acute and chronic complications result in a major impact on health-related quality of life (HRQoL) of PWH.

The mainstay of treatment in PWH is factor replacement therapy, for either prevention of bleeding (prophylaxis) or treatment of bleeding on an on-demand basis [6]. Prophylaxis has been shown capable of maintaining joint status and function [6], but adequate prophylaxis requires lifetime self-administration of factor concentrate two to three times per week. Moreover, PWH who suffer from haemophilic arthropathy require a multimodal approach, including medical treatment, surgery, rehabilitation and exercise [7,8,9]. Assessment of patient-important outcomes beyond bleeding frequency and functional status, including burden of treatment, impact on lifestyle and life choices, is a major aspect that needs to be quantified. Recently, the National Hemophilia Foundation, McMaster University Guideline on Care Models for Haemophilia Management, identified the important outcomes that patients value [10]. Those outcomes are mortality, missed days of school or work, number of emergency room visits, length of hospital stay, quality of life, joint status, educational attainment, patient adherence and patient knowledge. However, bleeding or bleeding rates were not considered as an important outcome.

Research including or principally focusing on real-world evidence and patient-reported outcomes (PRO) is increasingly valued by relevant stakeholders, including governments, regulators [11,12,13], health care agencies, health technology assessment (HTA) agencies [14], private payers and policy makers [15, 16]. Patients have unique perspectives and may consider issues differently than regulators, manufacturers, scientists, clinicians and payers [11]. The ability to collect and interpret relevant PRO to support the implementation of the prophylactic treatment, home care and integrated disease management (“comprehensive care”) is becoming more and more relevant to ensure optimal care to PWH [12, 15]. Over the last few years, direct patient involvement in designing, conducting and evaluating research has emerged as a theme in Europe and North America to ensure research is centered on patients and their needs [13].

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project is a research initiative conducted by PWH for PWH, with the specific aim to contribute PRO relevant to haemophilia by direct patient involvement in the design, conduct, analysis and reporting of patient-centered outcome research in the field of haemophilia.


General objectives

The PROBE Project aims to implement a structured data collection of PRO across several countries and cover a wide spectrum of health economic environments, to build a robust evidence base for comparative effectiveness, outcome research, evidence-based decision making and advocacy. To accomplish these overarching goals, three intermediate objectives have been identified for this phase of research: (a) develop a patient-led research network, (b) develop a standardized questionnaire to gather PRO and (c) perform a feasibility study. Figure 1 demonstrates the flow diagram of the process of the PROBE Project.

Fig. 1
figure 1

Flow diagram of the PROBE study

The research group

Upon a call to action [16] of the PROBE principal investigator (MS), a group of patients (RC, BOM, DN, DP, MS), supported by an epidemiologist (AI), an expert in outcome research (MN), an expert in management science and economic engineering systems (JS) and representatives of patient organizations (NF, BOM, DP), convened as co-investigators to form the PROBE research group (investigators) of the Patient Outcomes Research Group Ltd. (PORG) (Washington, DC, USA), the enterprise founded to administer the independent investigator-initiated research and grant funds the group has secured (see the “Acknowledgements” section). CC, a PhD candidate in Health Research Methodology at McMaster University, has worked closely with the investigators to support the technical aspects of the project development and data analysis. PORG has entered a research agreement with the Health Information Research Unit at McMaster University, Hamilton, ON, Canada, where the PROBE research database was established.

Co-investigators RC, NF, AI, DN, DP, JS, MN and BOM joined the group subsequently. PORG was incorporated in Washington, DC, USA, on 6 June 2016.

The development of a patient-led research network

The investigators identified and invited a selected group of national haemophilia patient non-governmental organizations (NGOs) to join the PROBE Project forming the PROBE research network. The proposed return for the investment were discussed with each NGO representative before developing a structured research protocol (NCT02439710). The selection of the countries for the pilot was performed by the investigators based on the following parameters: regions (North America, South America, Europe, Western Pacific, Asia or Africa), diversity in access to treatment product, health care system development level, health benefit coverage model and payer typology and local capacity to implement the requested operations. Each participating NGO designated a local investigator who managed the recruitment of study participants and executed the feasibility assessment of PROBE in their country.

The development of the PROBE questionnaire

The PROBE questionnaire was developed, refined and finalized by the PROBE research group, with input at several stages from local investigators and patient representatives belonging to NGOs within the PROBE research network. The PROBE questionnaire was developed with the dual objective of enabling fast and efficient collection of relevant information for advocacy purposes directly from patients and generating broad awareness of the importance of research led by patients for patients. It was explicitly discussed within the research network that additional scientific aspects of the PROBE questionnaire development and its characteristics would be pursued during later stages. As well, it was clearly stated that the prototypal version of the PROBE questionnaire was not expected to be the only or even main questionnaire developed by the research group.

The questionnaire was developed beginning with a brainstorming exercise of 48 participants from 18 countries. After being primed with a presentation reviewing existing tools measuring PRO, the participants were tasked with identifying and ranking key PRO and issues related to their measurement and evaluation. The PROBE research group summarized the results of the brainstorming exercise and produced a first draft of a questionnaire. The questionnaire was refined using multiple focus groups of PWH and people not personally affected by haemophilia. A full psychometric analysis including a validation study and test-retest reliability study was scheduled upon the successful completion of this refinement phase. They were performed and are reported elsewhere (manuscript submitted). Once all input from the focus groups were incorporated, the questionnaire was finalized by assessment for readability using the Flesch-Kincaid Grade Level classification to judge reading level [available at], edited accordingly and translated into all major languages spoken in the countries participating in the PROBE research network.

The feasibility study

The usability and properties of the finalized PROBE questionnaire were tested in a study involving individuals recruited by the NGOs.

Study population and enrollment

Participants were recruited through NGOs utilizing their existing membership rosters, social media outlets and meetings or events. Participants were required to meet one of two simple inclusion criteria: (1) PWH (haemophilia A or B with any degree of disease severity) or (2) “Controls” (individuals with no bleeding disorders). Except where required by local regulation, no pre-defined age limits were imposed on study participation. Investigators planned a post hoc analysis to assess a minimum age or cut off standard for PROBE data analysis. Based on the analysis, investigators agreed to include participants who were greater than age 10, a point at which responses were no longer interpretable or logically consistent with anticipated responses. Additionally, PWH typically begin to learn self-management and self-infusion skills in early adolescence (10–12.5 years) [17] which further supports adoption of the age limit selected by the investigators. Parents and caregivers of PWH were instructed to take the survey for themselves (as Controls) and not to answer for their child. Recruitment of approximately 50 participants (as a sum of PWH and Controls) per each of the participating countries, aiming at a minimum of 600 filled questionnaires across all countries, was planned.

Ethical considerations and privacy

The academic partner hosting the PROBE Project database (McMaster University) obtained Review Ethical Board approval and Privacy Officer clearance for PROBE from the Hamilton Integrated Research Ethics Board. Participating NGOs obtained or did not seek ethical approval depending on the local regulation for questionnaire-based studies led by patients. Customary processes were implemented to protect individual patient identities. Specifically, no patient identifier or personal information was collected as part of the study. Upon completion, questionnaires were immediately collected by local country investigators, bundled and shipped directly to the data coordinating center at McMaster University for data entry. Even though data were collected at the individual PWH and Control level, reports were limited to aggregate data to perform comparison of outcomes at the population level.

Outcome measures

The principal objective of the study was to assess feasibility and impact of implementing the PROBE questionnaire by the participating NGO, measured by staff and volunteer time required, cost incurred and barriers encountered. Free text comments and questions on the questionnaire were invited from participating NGOs via a separate questionnaire (Additional file 1).

Data analysis

Questionnaires were filled on paper and shipped to the data coordinating center at McMaster University for input into the PROBE electronic database. Descriptive statistical analysis was used as appropriate. Response rate was measured as a proportion of respondents returning the survey. Time to completion for each participant was collected as an ancillary question with the study questionnaire, and cost per completed survey was calculated by dividing the total cost (converted to USD) reported by the NGOs with the number of collected surveys.


Development of the patient-led research network

We successfully engaged national haemophilia organizations from 18 countries to participate in the PROBE Project. Patients from those national haemophilia organizations joined the process of questionnaire development. Over 500 participants were enrolled for the feasibility study through the PROBE research network.

Development, refinement and finalization of the PROBE questionnaire


Early papers that pioneered the concept of collecting comparative outcome data across countries within the haemophilia community informed the concept development for PROBE [14, 18]. Forty-eight delegates from 18 countries and a range of backgrounds within the haemophilia community (PWH, parents, caregivers, haemophilia specialists and researchers) gathered at the Haemophilia Experiences, Results and Opportunities Summit (HERO Summit). A workshop within the HERO Summit was dedicated to identifying and agreeing on key issues related to data capture, outcome measurement and assessment. Over 2 days, delegates discussed the lack of patient-reported outcome data and widely used PRO assessment tools to measure the full range of effects of comprehensive/expert care, home treatment and specific treatment regimens; identified opportunities and issues in developing a patient research framework for establishing appropriate metrics; listed and ranked outcomes important to PWH, health care professionals, governments and payers along with covariates to consider, surrogates and alternative data elements; and designed a framework to pilot a research project. Critical outcomes and relevant metrics of importance to the haemophilia community were identified (including quality of life, family burden, education/school, employment, treatment approaches, therapeutic outcomes and activities of daily living). These outcomes and related identified metrics provided the basis for the draft version of the PROBE questionnaire and feasibility study. The final core set of outcomes was ultimately determined through group discussion of all delegates. Table 1 summarizes the identified outcomes of importance and metrics to consider.

Table 1 Summary of the outcomes of importance and metrics to consider


Focus groups of PWH were used for testing the draft version of the PROBE questionnaire. Three parallel focus groups were organized in conjunction with a planned Global Advocacy Leadership Summit (Global Leadership Summit) representing 18 countries (Argentina, Australia, Brazil, Canada, Colombia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, The Netherlands, New Zealand, Spain, the UK, the USA and Venezuela). Thirty-seven subjects participated in the focus groups including 20 PWH and 17 participants without a bleeding disorder (e.g. haemophilia carriers, haemophilia specialists, nurse practitioners and physiotherapists). The focus group participants reviewed the introductory description of the PROBE project, stated objectives and provided further insights on the draft questionnaire content, clarity and relevance. After the focus groups, additional one-on-one interviews were conducted with some focus group participants to further clarify the focus group input. Interviews were continued until there were no more questions about the meaning of questionnaire items. In brief, patient focus groups were instrumental in helping to shape the questionnaire definitions of acute and chronic pain and identify items for pick lists of potential responses, e.g. areas of daily living where they had difficulty, and relevant comorbidities, e.g. oral health-related and gynecological issues. Questions were reworded using both patient-friendly terminology or split in two versions to compare clinical and patient-friendly definitions, e.g. for target joints. In several instances, options for the answers were expanded to cover the need of different countries, e.g., when asking about assistive devices in use. The contribution of the focus group in terms of wordsmithing, editing and clarification process was key to improve clarity, crispness and face validity for living experiences of the patients.


The questionnaire was reassessed by the investigators for completeness of the questionnaire for assessing all important outcomes, clarity and face validity. Investigators sought additional feedback by inviting comment on the redrafted questionnaire from patient representatives from some of the countries that participated in the Global Leadership Summit, and not otherwise represented by the home countries of the investigators. The US English version of the questionnaire was reviewed and assessed for readability using the Flesch-Kincaid Grade Level classification to judge the reading level [available at]. After editing, the text received a Flesch-Kincaid grade level of 7.6. The PROBE questionnaire was then translated and localized for 18 countries using an 8th grade language standard. Twenty local versions were produced: English (Australia, Canada, England, Ireland, New Zealand, USA), French (Canada, France), German (Germany), Hungarian (Hungary), Italian (Italy), Japanese (Japan), Dutch (The Netherlands), Portuguese (Brazil) and Spanish (Argentina, Colombia, Mexico, Spain, the USA and Venezuela). Language-specific versions were produced using the standard forward-backward technique and checked for appropriateness by at least one mother tongue field expert. The professional translation agency CETRA Language Solutions (Elkins Park, PA, USA) was contracted for the translation and grade level scoring. Country-specific language versions of the EuroQol 5-dimension 5-level instrument (EQ-5D-5L), a standardized measure of health status developed by the EuroQol group, consists of the following dimensions, mobility, self-care, usual activities, pain or discomfort and anxiety or depression, and the EuroQol visual analog scale (EQ-VAS) were incorporated and used with permission of the EuroQol Research Foundation [19]. The EQ-5D-5L and EQ-VAS were incorporated in the PROBE questionnaire in a format equivalent to their source versions without alteration.

The PROBE questionnaire

The PROBE questionnaire utilized in the feasibility assessment had a total of 29 questions (note: Based upon lessons learned from this feasibility assessment and subsequent phases of research, the PROBE questionnaire has been minimally updated and refined for use in future phases of research). For this research phase, Section I asks for demographic data (country, gender, body weight, age, education and marital and family status) and Section III asks for “haemophilia-related questions” (disease severity, inhibitor status and history, bleeding frequency and history, treatment regimen and history and presence of target joint(s) and range of motion limitations). These two sections (Section I and Section III) do not cover any PRO domains but provide information needed to explore and interpret the properties of the PRO sections. Should the PROBE survey be run as part of a clinical study or haemophilia registry, these parts could be omitted if otherwise covered and available for analysis. The other sections of the questionnaire cover the following domains: pain, independence, activities of daily living, educational attainment, employment and relationships. Section II, “general health problems”, includes the use of mobility aids and assistive devices, use of pain medication, presence of and how acute pain and chronic pain interfere with daily life, difficulty with daily activities, surgical history and concurrent medical problems and work/school life. Scaling responses are dichotomous (yes or no) and frequency. Frequency questions are answered on a 7-point Likert scale (never, rarely, occasionally, sometimes, frequently, very frequently and all of the time). Section IV includes the EQ-5D-5L and the EQ-VAS of global health [19].

The feasibility study

Patient organizations from 17 of the 18 mid to highly developed countries that attended the Barcelona Summit enrolled to participate in this study. Figure 2 depicts country participation. Each NGO distributed the PROBE questionnaire either by post, e-mail, at meetings, in-person or using other methods (clinic, camp or webpage). Figure 3 depicts the number of participants by country. Participants filled the questionnaire from April 2015 to December 2015. A total of 656 responses were collected and included in the analysis. Mean age was 41.9 years (SD 17.0). Of these, 353 were PWH with type A, 78 PWH with type B, 212 participants had no bleeding disorder (control population) and 13 were unknown as to bleeding disorder status.

Fig. 2
figure 2

Participating countries: Argentina (Cordoba Chapter), Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, The Netherlands, New Zealand, Spain, the UK, the USA, Venezuela

Fig. 3
figure 3

Number of participants by country

The median response rate by country was 35.5% (Q1, Q3—14.0%, 78.0%). Fifty percent of the responders filled out the questionnaire on the same day they received it. The rest of participants returned the questionnaire 1 to 42 days after. Time to completion is shown in Fig. 4. Most participants (474, 71.28%) completed the questionnaire within 15 min, and all participants completed it within 30 min. Table 2 shows the time devoted by staff and volunteers to implement the study by country. Forty percent of NGOs rated the number of hours used to run the survey as “minimal”, 13% as “moderate”, 20% as “acceptable” and 3% as “significant” (23% did not respond for this item). Table 3 summarized the major themes of the barriers identified by the NGOs in implementing the study reported.

Fig. 4
figure 4

Time to completion of the PROBE questionnaire

Table 2 Staff time and cost to implement the PROBE questionnaire by country
Table 3 List of barriers of carrying out the PROBE study


PROBE Project study results demonstrated the feasibility of planning and implementing a patient-led research network to explore PRO. The PROBE research group developed and tested a survey instrument aimed at collecting PROs in PWH and Controls. A network of NGOs in 17 countries, who collected 656 surveys using 20 localized language versions, was established. Results have demonstrated face validity, ease of administration and a short compilation time with minimal impact on NGO human and economic resources.

The true element of novelty of the PROBE Project is the leading role of the patients. There is an increasing awareness of the value of patient involvement in research [20]. The European Organization for Rare Diseases (EURORDIS) conducted a survey of 772 patient organizations [21]. This study found that non-financial support of patient organizations included facilitation of research projects and clinical trials by highlighting patients’ needs and expectations [21]. In the field of haemophilia, the PROBE Project is one of the few to outline the value and potential of direct patient involvement in planning and conducting research. The results of this study demonstrate the potential for an enhanced role of haemophilia patient organizations’ ability to implement research studies, collect patient-reported outcomes in a real-world setting and contribute credible data suitable for use in evidence-based decisions.

A second element of novelty is the PROBE questionnaire. The main goal in developing the PROBE questionnaire was to enable the collection of data to be used to improve treatment for haemophilia, including supporting comparative effectiveness analysis. For those health care settings moving toward value-based health care [22, 23], the capacity to measure and compare the impact of disease and treatment interventions on the life experiences of patients is critical. In this perspective, it is essential to measure HRQoL with a non-specific instrument, to allow comparison with medical interventions in other disease fields. The systematic review of the literature confirmed the previous finding that EQ-5D was one of the generic tools used most frequently in studies investigating HRQoL in PWH [24]. For this reason, the EQ-5D-5L was included as part of the PROBE questionnaire. To support comparison of alternative treatment modalities and intensities, a set of haemophilia-specific questions, which will be tested for their discrimination capacity and responsiveness in subsequent phases of the PROBE development, was included. The face and content validity, performed as part of this study, revealed that the items of PROBE questionnaire were appropriate for assessing the PRO of interest.

A third novel approach of the PROBE Project was to administer the PROBE questionnaire to both PWHs and participants without bleeding disorders (Controls). For Controls, the questionnaire surveyed all the questions in Sections II and III, whereas the haemophilia-related health questions were omitted for participants without a bleeding disorder. Generating a large sample of benchmark measures in the non-haemophilia population across many countries will be critical in assessing the impact of haemophilia on PRO beyond the baseline impact that age, comorbidities and life events have on all people. To the investigators’ knowledge, few other PRO tools [25,26,27] have developed a similar approach.

The PROBE questionnaire was designed to be concise. Seventy-one percent of the participants completed the questionnaire within 15 min. Previous studies have shown that a shorter form of questionnaires was preferred by the participants [28, 29]. As a comparison, the Hemofilia-QoL tool is comprised of 68 items in 8 domains (physical health, physical role, joint damage, pain, treatment satisfaction, emotional functioning, mental health and social support) and is designed for adult haemophilia patients and cannot be used to compare with participants without haemophilia [27]. The interest of health care agencies, private payers and policy makers for patient-reported outcomes (PRO) is continuously increasing. Cost and expertise to develop a robust and reliable data collection and analysis plan is a known challenge for NGOs. There is a substantial need to improve capacity to collect and interpret relevant PRO data to support implementation of patient-centered research and advocacy to obtain optimal care in haemophilia. PROBE has demonstrated that it can reliably address this need and its related challenges through establishment of a low-cost, low-burden and reliable data collection framework.

There are some limitations in the PROBE study design. The response rate in the pilot study has been inferior to that in other formal questionnaire development processes, including in the field of haemophilia [30]. However, the response rate obtained should be considered against the pragmatic design of the feasibility study. Given the extensive iterative process of survey development, investigators assessed that larger sample sizes were not required to demonstrate feasibility of administration by NGOs, to assess time to completion or further demonstrate content and clarity which were the primary outcome measures for this phase of research. The questionnaire has been voluntarily administered to patients by each participating patient organization, without dedicated research personnel. Each NGO decided how to distribute the questionnaire to the participants, which certainly impacted the response rate, but also informed the investigators on future best practice to guide NGOs participating in subsequent phases.

PROBE was not specifically designed to investigate PRO in children. As noted in the study population description above, the PROBE study inclusion criteria and participant selection process allowed participants greater than age 10 to participate. Investigators will use these responses, jointly with the experiences gained with age-specific tools in subsequent analysis.

Finally, there are several factors that may impact the cost of questionnaire implementation in multiple countries which we have not been able to account for completely, for example, wage rate, cost of transportation rate, cost of mailing rate or number of questionnaire distributed and collected. Cost (in USD) to implement the survey varied from $22 to $543 (for a median of $8.50 per participant, range $1.20 to $64.30) with printing and postage (to mail out the survey or ship completed surveys back to the investigation team) being the most commonly reported expenditures. Those reporting higher cost included costs for NGO staff (local country investigators) to travel to a meeting location where the PROBE questionnaire was to be administered. The cost per questionnaire provided should be considered as a guide, not a final estimate.


PROBE has developed a concise questionnaire for assessing PRO in PWH and people without a bleeding disorder. The PROBE questionnaire combines generic and disease-specific outcomes in 29 items, requiring 15 min for completion. PROBE proved the feasibility to engage diverse patient communities in the structured generation of real-world outcome research at all stages. Future studies will explore the measurement properties of the PROBE questionnaire in the research network.



EuroQol visual analog scale


EuroQol 5-dimension 5-level


European Organization for Rare Diseases


Haemophilia Experiences, Results and Opportunities Summit


Health-related quality of life


Health technology assessment


Non-governmental organization


Patient-reported outcome


Patient Reported Outcomes, Burdens and Experiences


Person living with haemophilia


  1. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor V, Factor IXS. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.

    CAS  PubMed  Google Scholar 

  2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.

    Article  CAS  PubMed  Google Scholar 

  3. De Kleijn P, Gilbert M, Roosendaal G, Poonnose PM, Narayan PM, Tahir N. Functional recovery after bleeding episodes in haemophilia. Haemophilia. 2004;10 Suppl 4:157–60.

    Article  CAS  PubMed  Google Scholar 

  4. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSS J. 2010;6(1):37–42.

    Article  PubMed  Google Scholar 

  5. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. multicenter hemophilia cohort study. J Acquir Immune Defic Syndr. 1994;7(3):279–86.

    CAS  PubMed  Google Scholar 

  6. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.

    Article  CAS  PubMed  Google Scholar 

  7. Goddard NJ, Mann HA, Lee CA. Total knee replacement in patients with end-stage haemophilic arthropathy: 25-year results. J Bone Joint Surg Br. 2010;92(8):1085–9.

    Article  CAS  PubMed  Google Scholar 

  8. Tsoukas C, Eyster ME, Shingo S, Mukhopadhyay S, Giallella KM, Curtis SP, Reicin AS, Melian A. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood. 2006;107(5):1785–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Blamey G, Forsyth A, Zourikian N, Short L, Jankovic N, De Kleijn P, Flannery T. Comprehensive elements of a physiotherapy exercise programme in haemophilia—a global perspective. Haemophilia. 2010;16 Suppl 5:136–45.

    Article  CAS  PubMed  Google Scholar 

  10. Pai M, Santesso N, Yeung CH, Lane SJ, Schunemann HJ, Iorio A. Methodology for the development of the NHF-McMaster guideline on care models for haemophilia management. Haemophilia. 2016;22 Suppl 3:17–22.

    Article  CAS  PubMed  Google Scholar 

  11. Lowe MM, Blaser DA, Cone L, Arcona S, Ko J, Sasane R, Wicks P. Increasing patient involvement in drug development. Value Health. 2016;19(6):869–78.

    Article  PubMed  Google Scholar 

  12. U.S. FDA. The voice of the patient: a series of reports from FDA’s patient-focused drug development initiative. Retreived from

  13. Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, Joos A, Metcalf M, Regnante J, Sargeant I, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929–39.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Noone D, O'Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia. 2013;19(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  15. U.S. FDA. Enhancing benefit-risk assessment in regulatory decision-making. Retreived from

  16. Skinner MW. WFH: closing the global gap—achieving optimal care. Haemophilia. 2012;18 Suppl 4:1–12.

    Article  PubMed  Google Scholar 

  17. Schrijvers LH, Schuurmans MJ, Fischer K. Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. Haemophilia. 2016;22(4):499–506.

    Article  CAS  PubMed  Google Scholar 

  18. Noone D, O'Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries. Haemophilia. 2011;17(5):e842–3.

    CAS  PubMed  Google Scholar 

  19. EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.

    Article  Google Scholar 

  20. Kaye J, Curren L, Anderson N, Edwards K, Fullerton SM, Kanellopoulou N, Lund D, MacArthur DG, Mascalzoni D, Shepherd J, et al. From patients to partners: participant-centric initiatives in biomedical research. Nat Rev Genet. 2012;13(5):371–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mavris M, Le Cam Y. Involvement of patient organisations in research and development of orphan drugs for rare diseases in europe. Mol Syndromol. 2012;3(5):237–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81.

    Article  CAS  PubMed  Google Scholar 

  23. Porter ME, Larsson S, Lee TH. Standardizing patient outcomes measurement. N Engl J Med. 2016;374(6):504–6.

    Article  CAS  PubMed  Google Scholar 

  24. Remor E, Young NL, Von Mackensen S, Lopatina EG. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia. 2004;10 Suppl 4:30–4.

    Article  CAS  PubMed  Google Scholar 

  25. Young NL, Bradley CS, Blanchette V, Wakefield CD, Barnard D, Wu JK, PJ MC. Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes—Kids Life Assessment Tool (CHO-KLAT). Haemophilia. 2004;10 Suppl 1:34–43.

    Article  CAS  PubMed  Google Scholar 

  26. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer. 2006;47(3):305–11.

    Article  PubMed  Google Scholar 

  27. Arranz P, Remor E, Quintana M, Villar A, Diaz JL, Moreno M, Monteagudo J, Ugarriza A, Soto I, Perez R, et al. Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia. Haemophilia. 2004;10(4):376–82.

    Article  CAS  PubMed  Google Scholar 

  28. Dillman DA, Sinclair MD, Clark JR. Effects of questionnaire length, respondent-friendly design and a difficult question on response rates for occupant-addressed census mail surveys. Public Opinion Quarterly. 1993;57(3):289–304.

    Article  Google Scholar 

  29. VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof. 2007;30(4):303–21.

    Article  PubMed  Google Scholar 

  30. Manco-Johnson M, Morrissey-Harding G, Edelman-Lewis B, Oster G, Larson P. Development and validation of a measure of disease-specific quality of life in young children with haemophilia. Haemophilia. 2004;10(1):34–41.

    Article  CAS  PubMed  Google Scholar 

Download references


PROBE investigators thank the patient organizations that participated in Phase 1: Fundación de la Hemofilia (Argentina) Cordoba Chapter, Hemophilia Foundation Australia, Federaçao Brasileira de Hemofilia (Brazil), Canadian Hemophilia Society, Association Française des Hémophiles (France), Deutsche Hämophiliegesellschaft (Germany), Magyar Hemofilia Egyesulet (Hungary), Irish Haemophilia Society, Federazione delle Associazioni Emofilici (Italy), National Hemophilia Network of Japan, Federación de Hemofilia de la República Mexicana (Mexico), Nederlandse Vereniging van Hemofilie-Patiënten (The Netherlands), Haemophilia Foundation of New Zealand, Federación Española de Hemofilia (Spain), The Haemophilia Society (United Kingdom), National Hemophilia Foundation (United States) and Asociación Venezolana para la Hemofilia (Venezuela)

The PROBE investigators thank Novo Nordisk for their inclusion of the work stream on measuring outcomes in the Novo Nordisk HERO Summit 27–28 June 2013 held in The Hague, The Netherlands, and Bayer Healthcare for allowing the focus groups to be conducted during the Global Haemophilia Advocacy Leadership Summit held in Barcelona, Spain, 21–22 January 2015.


PROBE is an independent investigator-led research project with grant/research support from Baxalta, now part of Shire, Bayer, Bioverativ, CSL Behring, Novo Nordisk, Sobi and Roche with administrative support provided by the US National Hemophilia Foundation.

Availability of data and materials

The data used in this study are not publicly available due to ethical and legal restrictions.

Author information

Authors and Affiliations



MWS, AI, RC, NF, MN, DN, BOM, DP and JS conceptualized the study. CC performed the data collection and statistical analysis. CC, AI and MS drafted the manuscript. All authors critically reviewed the manuscript. All authors approved the final manuscript.

Corresponding author

Correspondence to MW. Skinner.

Ethics declarations

Ethics approval and consent to participate

Approval from the institutional review board or ethics committee was obtained. A participant description and disclaimer was provided with each questionnaire, and then, the participants were invited to proceed if they agreed or have an opportunity to ask questions. No identifiable patient information was disclosed as part of the study.

Consent for publication

Not applicable.

Competing interests

CC has no potential conflict of interest. AI received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. AI received non-financial support from US National Hemophilia Foundation. RC received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. RC received non-financial support from US National Hemophilia Foundation. MN received grants from Bayer, Pfizer, Genentech, Biogen, Novo Nordisk, Baxter and CSL Behring. MN received personal fees from Bayer and Biogen. DN received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. DN also received non-financial support from US National Hemophilia Foundation. BOM received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. BOM received non-financial support from US National Hemophilia Foundation. MS received grants from Baxalta now part of Shire, Bayer, Bioverativ, Sobi, Novo Nordisk and Roche. MS also received non-financial support from US National Hemophilia Foundation.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Participating NGO evaluation report. (DOCX 24 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skinner, M., Chai-Adisaksopha, C., Curtis, R. et al. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot Feasibility Stud 4, 58 (2018).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: